Details of the Drug

General Information of Drug (ID: DMCMOS8)

Drug Name
L-cysteine
Synonyms
52-90-4; Cystein; Half-cystine; (R)-Cysteine; Thioserine; (R)-2-Amino-3-mercaptopropanoic acid; L-(+)-Cysteine; L-Cystein; (2R)-2-amino-3-sulfanylpropanoic acid; beta-Mercaptoalanine; Half cystine; FREE CYSTEINE; Cysteine, L-; L-Cys; L-Alanine, 3-mercapto-; L-Zystein; H-Cys-OH; Cisteinum [Latin]; L-2-Amino-3-mercaptopropionic acid; Cisteina [Spanish]; cisteina; Polycysteine; Cysteinum; Cisteinum; (R)-2-Amino-3-mercaptopropionic acid; L Cysteine; alpha-Amino-beta-thiolpropionic acid; L-2-Amino-3-mercaptopropanoic a
Indication
Disease Entry ICD 11 Status REF
Amyloidosis 5D00 Approved [1]
Bronchiectasis CA24 Approved [2]
Bronchitis CA20 Approved [3]
Paracetamol poisoning N.A. Approved [4]
Non-small-cell lung cancer 2C25.Y Clinical trial [5]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 121.16
Logarithm of the Partition Coefficient (xlogp) -2.5
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 4
Chemical Identifiers
Formula
C3H7NO2S
IUPAC Name
(2R)-2-amino-3-sulfanylpropanoic acid
Canonical SMILES
C([C@@H](C(=O)O)N)S
InChI
InChI=1S/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1
InChIKey
XUJNEKJLAYXESH-REOHCLBHSA-N
Cross-matching ID
PubChem CID
5862
ChEBI ID
CHEBI:17561
CAS Number
52-90-4
DrugBank ID
DB00151
TTD ID
D0L4VI
INTEDE ID
DR2105
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Glutamate-cysteine ligase catalytic (GCLC) DESYL1F GSH1_HUMAN Substrate [6]
Glutamate-cysteine ligase regulatory (GCLM) DEEBDFT GSH0_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Amino acid transporter heavy chain SLC3A1 (SLC3A1) OT56V01A SLC31_HUMAN Regulation of Drug Effects [7]
Arsenite methyltransferase (AS3MT) OTNLWD0N AS3MT_HUMAN Post-Translational Modifications [8]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Gene/Protein Processing [9]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Gene/Protein Processing [9]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Post-Translational Modifications [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Systemic and cerebral amyloidosis. Ann Med. 1989;21(2):69-72.
2 Safety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review. Drug Saf. 2021 Mar;44(3):273-290.
3 Oxidation pathway and exacerbations in COPD: the role of NAC. Expert Rev Respir Med. 2016;10(1):89-97.
4 The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Curr Neuropharmacol. 2021;19(8):1202-1224.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4782).
6 The enzymes of glutathione synthesis: gamma-glutamylcysteine synthetase. Adv Enzymol Relat Areas Mol Biol. 1999;73:209-67, xii.
7 Characteristics of transport of selenoamino acids by epithelial amino acid transporters. Chem Biol Interact. 2009 Feb 12;177(3):234-41. doi: 10.1016/j.cbi.2008.09.008. Epub 2008 Sep 19.
8 The functions of crucial cysteine residues in the arsenite methylation catalyzed by recombinant human arsenic (III) methyltransferase. PLoS One. 2014 Oct 28;9(10):e110924. doi: 10.1371/journal.pone.0110924. eCollection 2014.
9 Differential susceptibility of nonmalignant human breast epithelial cells and breast cancer cells to thiol antioxidant-induced G(1)-delay. Antioxid Redox Signal. 2005 May-Jun;7(5-6):711-8. doi: 10.1089/ars.2005.7.711.